Drug Approval | December 20, 2025
Cosette Pharmaceuticals launches first generic CIPRO HC with 180 Days market exclusivity
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Subscribe To Our Newsletter & Stay Updated
